Search Results Search Sort by RelevanceMost Recent Case and Commentary Jul 2003 Drug Company Sponsorship of Clinical Conferences, Commentary 1 Robert Goodman, MD Two physicians assert that pharmaceutical companies' sponsorship of clinical conferences for residents and physicians represent a conflict of interest. Virtual Mentor. 2003;5(7):239-241. doi: 10.1001/virtualmentor.2003.5.7.ccas1-0307. AMA Code Says Jul 2003 The Code on Physicians' Relationship with Industry Audiey C. Kao, MD, PhD The AMA's Code of Medical Ethics provides ample guidance for the interactions between pharmaceutical companies and physicians. Virtual Mentor. 2003;5(7):263-264. doi: 10.1001/virtualmentor.2003.5.7.code1-0307. Medicine and Society Jul 2024 How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder? Elizabeth Salisbury-Afshar, MD, MPH, Catherine J. Livingston, MD, MPH, and Ricky N. Bluthenthal, PhD Equity requires full access to evidence-based OUD care, housing stability, and education and employment opportunities. AMA J Ethics. 2024;26(7):E562-571. doi: 10.1001/amajethics.2024.562. Policy Forum Jul 2024 How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice? Ellen L. Edens, MD, MPE, MA, Gabriela Garcia Vassallo, MD, and Robert Heimer, PhD Reconsider regulatory and clinical frameworks for prescribing long-term opioid therapy for pain and prescribing opioids to treat OUD. AMA J Ethics. 2024;26(7):E551-561. doi: 10.1001/amajethics.2024.551. Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. AMA J Ethics. 2024;26(7):E512-519. doi: 10.1001/amajethics.2024.512. Case and Commentary Jul 2024 When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond? Taleed El-Sabawi, JD, PhD and Kelly Gillespie, JD, PhD, RN Clinicians caring for patients with OUD should plan for possible disruptions of treatment caused by arrests and pretrial confinements. AMA J Ethics. 2024;26(7):E520-526. doi: 10.1001/amajethics.2024.520. Viewpoint Jul 2024 Opioid Epidemic Grief and Characterological Harm Reduction Christy A. Rentmeester, PhD Becoming callous, bitter, or resentful are harms we can suffer when grieving losses, especially at epidemic scale. AMA J Ethics. 2024;26(7):E587-590. doi: 10.1001/amajethics.2024.587. Health Law Jul 2024 What Should the US Learn From New York’s and Portugal’s Approaches to the Opioid Crisis? Maura McGinnity Some US localities are trying interventions modeled on international approaches to decriminalization. AMA J Ethics. 2024;26(7):E546-550. doi: 10.1001/amajethics.2024.546. Case and Commentary Jul 2024 When Are “Paraphernalia” Critical Medical Supplies? Adriane M. dela Cruz, MD, PhD, Donald Egan, MD, MPH, Sarah E. Baker, MD, MA, and John Z. Sadler, MD Evidence of harm reduction interventions’ morbidity and mortality benefits is abundant and of high quality. AMA J Ethics. 2024;26(7):E527-533. doi: 10.1001/amajethics.2024.527. Podcast Jul 2024 Author Interview: "Opioid Epidemic Grief and Characterological Harm Reduction” Dr Christy A. Rentmeester joins Ethics Talk to discuss her article: "Opioid Epidemic Grief and Characterological Harm Reduction.” Pagination First page « First Previous page ‹ Previous … Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Current page 19 Page 20 Page 21 Next page Next › Last page Last »
Case and Commentary Jul 2003 Drug Company Sponsorship of Clinical Conferences, Commentary 1 Robert Goodman, MD Two physicians assert that pharmaceutical companies' sponsorship of clinical conferences for residents and physicians represent a conflict of interest. Virtual Mentor. 2003;5(7):239-241. doi: 10.1001/virtualmentor.2003.5.7.ccas1-0307.
AMA Code Says Jul 2003 The Code on Physicians' Relationship with Industry Audiey C. Kao, MD, PhD The AMA's Code of Medical Ethics provides ample guidance for the interactions between pharmaceutical companies and physicians. Virtual Mentor. 2003;5(7):263-264. doi: 10.1001/virtualmentor.2003.5.7.code1-0307.
Medicine and Society Jul 2024 How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder? Elizabeth Salisbury-Afshar, MD, MPH, Catherine J. Livingston, MD, MPH, and Ricky N. Bluthenthal, PhD Equity requires full access to evidence-based OUD care, housing stability, and education and employment opportunities. AMA J Ethics. 2024;26(7):E562-571. doi: 10.1001/amajethics.2024.562.
Policy Forum Jul 2024 How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice? Ellen L. Edens, MD, MPE, MA, Gabriela Garcia Vassallo, MD, and Robert Heimer, PhD Reconsider regulatory and clinical frameworks for prescribing long-term opioid therapy for pain and prescribing opioids to treat OUD. AMA J Ethics. 2024;26(7):E551-561. doi: 10.1001/amajethics.2024.551.
Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. AMA J Ethics. 2024;26(7):E512-519. doi: 10.1001/amajethics.2024.512.
Case and Commentary Jul 2024 When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond? Taleed El-Sabawi, JD, PhD and Kelly Gillespie, JD, PhD, RN Clinicians caring for patients with OUD should plan for possible disruptions of treatment caused by arrests and pretrial confinements. AMA J Ethics. 2024;26(7):E520-526. doi: 10.1001/amajethics.2024.520.
Viewpoint Jul 2024 Opioid Epidemic Grief and Characterological Harm Reduction Christy A. Rentmeester, PhD Becoming callous, bitter, or resentful are harms we can suffer when grieving losses, especially at epidemic scale. AMA J Ethics. 2024;26(7):E587-590. doi: 10.1001/amajethics.2024.587.
Health Law Jul 2024 What Should the US Learn From New York’s and Portugal’s Approaches to the Opioid Crisis? Maura McGinnity Some US localities are trying interventions modeled on international approaches to decriminalization. AMA J Ethics. 2024;26(7):E546-550. doi: 10.1001/amajethics.2024.546.
Case and Commentary Jul 2024 When Are “Paraphernalia” Critical Medical Supplies? Adriane M. dela Cruz, MD, PhD, Donald Egan, MD, MPH, Sarah E. Baker, MD, MA, and John Z. Sadler, MD Evidence of harm reduction interventions’ morbidity and mortality benefits is abundant and of high quality. AMA J Ethics. 2024;26(7):E527-533. doi: 10.1001/amajethics.2024.527.
Podcast Jul 2024 Author Interview: "Opioid Epidemic Grief and Characterological Harm Reduction” Dr Christy A. Rentmeester joins Ethics Talk to discuss her article: "Opioid Epidemic Grief and Characterological Harm Reduction.”